References
- Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis. 2001; 32: 358–66.
- Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322–30.
- Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albos A. Risk of reactivation of a recent invasive fungal infec-tion in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single center experi-ence and review of the literature. Haematologica 1997; 82: 297–304.
- Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis.Clin Infect Dis. 2004; 39: 797–802.
- Cesaro S, Visintin G. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2005; 40: 1073–5.
- Marr KA, Boeckh M, Kim HW. Combination antifungal therapy for invasive aspergillosis Reply to Cesaro and Visintin. Clin Infect Dis. 2005; 40: 1075–6.
- Gayalda J, Martin MT, Lopez P, et al. Efficacy of nebu-lized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 2005; 49 (7): 3028–30.
- Ruiz I, Molina I, GayaIda J, et al. Safety and tolerability of nebulized liposomal amphotericin B in hematologic patients. Program and abstract of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology: Washington D.C., 2005; abstract n. M-977-2005
- Alter BP, Lipton JM. Bone marrow failure syndromes. In: Rudolph AM, Hoffman JIE, Rudolph CD, Fris: Rudolph's Pediatrics 20th Edition. Prentice Hall International: London 1996: 1185-93.
- Rex JH, Stevens DA. Systemic antifungal agents. In: Mandell GL, Bennett JE, Doolin R, eds: Principles and practice of infectious diseases. Churchill Livingstone: Philadelphia 2005: 502-514
- Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal ampho-tericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001; 45: 3487-96.
- Kontny U, Walsh TJ, Rossler J, Uhl M, Niemeyer CM. Successful treatment of refractory chronic disseminated can-didiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr Blood Cancer. 2006 Jan 27; [Epub ahead of print]
- Vehreschild JJ, Kruger K, Kurzai 0, Wickenhauser C, Behringer K, Tox U, Comely OA. Salvage therapy of refrac-tory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogene-ic stem cell transplantation. Mycoses. 2006;49 Suppl 1: 42–7.
- ViSCOli C. Combination therapy for invasive aspergillo-sis. Clin Infect Dis. 2004; 39: 803–805.
- Comely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal Amphotericin B (L-AMB) as initial therapy for inva-sive filamentous fungal infections (iffi): a randomized, prospec-tive trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005; 106: Abstract #3222
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408–15.
- Mattel D, Mordini N, Lo Nigro C, et al. Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.Bone Marrow Transplant. 2002; 30: 967–70
- Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004; 48: 2166–72.
- Faraci M, Lanino E, Dallorso S, et al. Mesial temporal sclerosis—a late complication in four allogeneic pediatric recipients with persistent seizures after an acute episode of cyclosporine-A neurotoxicity. Bone Marrow Transplant. 2003; 31: 919–22.
- Faraci M, Lanino E, Dini G, et al. Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology. 2002; 59: 1895–904.